[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stroke-ischemic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stroke-ischemic":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,110,0,25,[9,52,76,104,135,170,219,246,268,288,308,335,358,386,413,439,461,488,514,536,562,591,616,642,667],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":35,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100524838","phase-4-prevention-of-infection-of-the-respiratory-tract-through-application-of-non-invasive-methods-of-secretion-suctioning-100524838",false,"NCT06113939","Prevention of Infection of the Respiratory Tract Through Application of Non-Invasive Methods of Secretion Suctioning","Prevention of Infection of the Respiratory Tract by Applying Methods That Are Non-Invasive for Extraction of Secretions. An Open Label, Randomized, Assessor-blinded, Pilot Trial.","PIRAMIDES","Inclusion criteria\n\n1. Endotracheal intubation with an anticipated duration \\> 48 hours.\n2. High risk of early respiratory infection associated with a diagnosis of:\n\n   1. Severe trauma.\n   2. Severe traumatic brain injury.\n   3. Ischaemic or haemorrhagic stroke.\n   4. Other causes of impaired consciousness: post-resuscitated cardiac arrest status, intoxications, acute infections or diseases of the central nervous system, seizures.\n3. Informed consent signed by the patient or, when impossible due to clinical status, by their legal representative, with re-consent by the patients themselves upon regaining capacity (section 15).\n\nExclusion criteria\n\n1. Intubation with an anticipated duration \\\u003C 48 hours.\n2. Foreseeable ominous prognosis within \\\u003C 7 days.\n3. Already established indication for systemic antibiotic therapy, either for suspected aspiration pneumonia with radiological pulmonary infiltrate or for suspected non-respiratory source infection.\n4. Active haemoptysis or pulmonary haemorrhage.\n5. Unstable chest.\n6. Undrained pneumothorax (inclusion may be considered once drained).\n7. Known allergy or intolerance to beta-lactam antibiotics.","ALL","18 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","Adults who are unconscious or severely ill and need a breathing tube connected to a ventilator are at high risk of developing a lung infection (pneumonia) within the first few days in the intensive care unit. This early pneumonia affects up to 30 to 50 % of certain high-risk patients, prolongs the time on the ventilator and in hospital, and increases the use of antibiotics.\n\nTwo strategies are commonly used today to try to prevent this infection: a short, three-day course of an intravenous antibiotic, and removal of secretions from the airway with a sterile suction catheter. Both have limitations - antibiotics can favour the growth of resistant bacteria, and catheter suctioning is uncomfortable and may injure the airway.\n\nPIRÁMIDES is a small (60-patient) pilot study that compares the current practice with two non-invasive, mechanical alternatives for keeping the airway clear: a continuous low-pressure suction system built into a special breathing tube, and a device that produces a gentle, programmed \"artificial cough\" through the ventilator. Adult patients who are intubated for severe trauma, severe brain injury, stroke, resuscitated cardiac arrest or other causes of decreased consciousness are randomly assigned, in equal numbers, to one of the three approaches and followed for 14 days, with a final visit at day 90.\n\nThe main goal is to find out which of the three strategies best prevents early pneumonia, and which provides the best overall result for patients when survival, severity of infection, need for additional antibiotics and side effects are considered together. To make these comparisons as fair as possible in an open-label study, an independent committee of doctors not involved in patient care reviews each suspected pneumonia case without knowing which strategy the patient received. The results will help design a larger trial to confirm which approach is safest and most effective for preventing early pneumonia in critically ill patients on a ventilator.",[28,29,30,31,32,33,34],"Intubation Complication","Stroke, Ischemic","Stroke Hemorrhagic","Head Trauma","Cardiac Arrest","Ventilator Associated Pneumonia","Airway Clearance Impairment",[36,37,38],"ventilator-associated pneumonia","prevention","airway clearance","NOT_YET_RECRUITING","2026-06-25",{"date":42,"type":43},"2026-06-29","ACTUAL",{"date":45,"type":22},"2026-09-15",{"date":47,"type":22},"2029-06-30",{"name":49,"class":50},"Hospital San Carlos, Madrid","OTHER",1,{"id":53,"slug":54,"hasResults":12,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":51},"100622097","phase-3-hr-mri-directed-tirofiban-therapy-for-late-window-acute-ischemic-stroke-tian-100622097","NCT07379190","HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN)","Efficacy and Safety of Tirofiban Therapy in Acute Ischemic Stroke Patients Beyond the Time Window Guided by High-Resolution Magnetic Resonance Imaging","Inclusion Criteria:\n\n1. Age ≥ 18 years old;\n2. Acute ischemic stroke (AIS) in the anterior intracranial circulation (internal carotid artery system) confirmed by clinical symptoms and imaging examinations;\n3. Time from symptom onset or last known normal state to randomization: \\> 24 hours and ≤ 7 days;\n4. Stroke subtype confirmed as intracranial large artery atherosclerosis (ICAS) by high-resolution vessel wall imaging (HR-VWI) according to the TOAST classification, with cardiogenic embolism and other etiologies excluded;\n5. Baseline National Institutes of Health Stroke Scale (NIHSS) score of 4-20 at the time of randomization;\n6. Signed informed consent form obtained from the patient or their legal representative.\n\nExclusion Criteria:\n\n1. Planned to receive reperfusion therapy (endovascular therapy or intravenous thrombolysis)；\n2. Intracranial hemorrhage confirmed by computed tomography (CT)；\n3. Definite or suspected cardiogenic embolism；\n4. History of atrial fibrillation or current electrocardiogram indicating atrial fibrillation；\n5. Acute ischemic stroke caused by other etiologies, such as Moyamoya disease, arterial dissection, arteritis, etc；\n6. Imaging examinations indicating that the area of the current cerebral infarction exceeds 1\u002F2 of the area of a single cerebral lobe;\n7. Known contraindications to antiplatelet therapy, including hematochezia, gastrointestinal bleeding, or any other hemorrhagic disorders;\n8. History of hypersensitivity to aspirin;\n9. Definite indication for anticoagulant therapy expected during the study period (e.g., atrial fibrillation, mechanical heart valve, deep vein thrombosis, pulmonary embolism, antiphospholipid antibody syndrome, hypercoagulable state, etc.);\n10. Complicated with malignant tumors, chronic hemodialysis, severe renal insufficiency (glomerular filtration rate \\[GFR\\] \\\u003C 30 ml\u002Fmin or serum creatinine \\[Cr\\] \\> 220 μmol\u002FL (2.5 mg\u002Fdl)), or severe hepatic insufficiency (serum alanine aminotransferase \\[ALT\\] \\> 2 times the upper limit of normal \\[ULN\\], or serum aspartate aminotransferase \\[AST\\] \\> 2 times the ULN);\n11. Severe heart failure (New York Heart Association \\[NYHA\\] Functional Classification Class III or IV);\n12. Complicated with severe non-cardiovascular comorbidities, with an estimated survival time \\\u003C 6 months;\n13. Concurrent new cerebral infarction in both anterior and posterior circulations;\n14. Inability to complete the follow-up procedures;\n15. Presence of other known neurological disorders that may complicate the follow-up;\n16. Concurrent participation in other therapeutic clinical trials with incomplete treatment and follow-up;\n17. Other conditions that the investigators consider inappropriate for enrollment in this study.",{"count":60,"type":22},458,[62],"PHASE3","This study aims to address the existing clinical challenges by introducing high-resolution magnetic resonance vessel wall imaging (HR-MRI), an advanced imaging technology, to achieve precise etiological classification in patients with acute ischemic stroke (AIS) beyond the time window. HR-MRI allows clear visualization of intracranial arterial wall structures and direct identification of key pathological features of the culprit vessel, including atherosclerotic plaques, vascular wall remodeling, and intracranial hemorrhage, thereby enabling reliable differentiation between intracranial atherosclerotic large artery atherosclerosis (ICAS-LAA) stroke and other etiological subtypes such as cardiogenic embolism. Based on the latest clinical demands and advances in imaging technology, this study intends to evaluate the efficacy and safety of tirofiban in patients with ICAS-LAA stroke beyond the time window under the precise guidance of HR-MRI. It is expected to provide high-level evidence-based medical evidence for this specific patient population and further optimize clinical diagnosis and treatment strategies.",[65,29,66],"Stroke, Acute","Cerebral Infarction","RECRUITING","2026-06-24",{"date":40,"type":43},{"date":71,"type":43},"2026-06-22",{"date":73,"type":22},"2029-05-01",{"name":75,"class":50},"Weifang Medical University",{"id":77,"slug":78,"hasResults":12,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":51},"100368519","urinary-disorders-in-subacute-patients-after-stroke-100368519","NCT04078373","Urinary Disorders in Subacute Patients After Stroke","Assessment and Treatment of Urinary Disorders in Patients in the Subacute Phase After Stroke","UIMK","Inclusion Criteria:\n\n* subacute patients after ischaemic or hemorrhagic stroke;\n* direct transfer from acute hospital to complex inpatient rehabilitation at our Institute.\n\nExclusion Criteria:\n\n* incontinence before stroke;\n* previous brain injury or other brain disease;\n* previous bladder or prostate surgery;\n* inability to ambulate before stroke;\n* terminal disease with expected survival less than three months.",{"count":85,"type":22},250,"OBSERVATIONAL","This observational study will address urinary disorders in subacute stroke patients. Patients without and with urinary disorders will be compared, and treatment outcome will be assessed among the latter.",[29,30,89],"Urinary Incontinence",[91,92,93,94],"stroke","inpatient rehabilitation","urinary disorders","treatment","2026-06-11",{"date":97,"type":43},"2026-06-15",{"date":99,"type":43},"2019-06-01",{"date":101,"type":22},"2026-10",{"name":103,"class":50},"University Rehabilitation Institute, Republic of Slovenia",{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":114,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":134},"100513302","the-fourth-left-atrial-appendage-occlusion-study-100513302","NCT05963698","The Fourth Left Atrial Appendage Occlusion Study","The Fourth Left Atrial Appendage Occlusion Study (LAAOS-4)","LAAOS-4","Inclusion Criteria:\n\n1. (a) Persistent or permanent atrial fibrillation OR (b) Paroxysmal atrial fibrillation in participants with a history of ischemic stroke or systemic embolism\n2. Increased risk of stroke, defined as a CHA2DS2-VASc stroke risk score of ≥ 4. \\[Note: the acronym CHA2DS2-VASc stands for congestive heart failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled), vascular disease, age 65 to 74 and sex category (female).\\]\n3. Treatment with oral anticoagulants (Vitamin K agonist or factor Xa inhibitor) for at least 90 days prior to enrollment, AND no documented plan to discontinue treatment with oral anticoagulants for the expected duration of the trial.\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years\n2. Current left atrial appendage thrombus\n3. Prior left atrial appendage occlusion or removal (surgical or percutaneous)\n4. Prior percutaneous atrial septal defect or patent foramen ovale closure\n5. Prior atrial fibrillation ablation unless evidence of recurrent qualifying atrial fibrillation present at least 30 days following ablation\n6. Planned atrial fibrillation ablation within 90 days of enrollment\n7. Individuals being treated with direct thrombin inhibitors\n8. Women of childbearing potential unless they agree to employ effective birth control methods throughout the study\n9. Anticipated life-expectancy of \\\u003C 2 years\n10. Patient unable or willing to give informed consent",{"count":113,"type":22},4000,[115],"NA","LAAOS-4 aims to determine if catheter-based endovascular left atrial appendage occlusion prevents ischemic stroke or systemic embolism in participants with atrial fibrillation, who remain at high risk of stroke, despite receiving ongoing treatment with oral anticoagulation.",[118,29,119],"Atrial Fibrillation","Systemic Embolism",[121,122,123,124],"WATCHMAN","Left Atrial Appendage (LAA)","LAA Device","Left Atrial Appendage Occlusion","2026-06-04",{"date":127,"type":43},"2026-06-08",{"date":129,"type":43},"2023-11-30",{"date":131,"type":22},"2029-12-01",{"name":133,"class":50},"Hamilton Health Sciences Corporation",140,{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":143,"targetDuration":144,"studyType":86,"phases":4,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":169},"100284863","neurovascular-product-surveillance-registry-100284863","NCT02988128","Neurovascular Product Surveillance Registry","NeuroVascular Product Surveillance Registry (PSR) Platform","INSPIRE","For MDT16056 and MDT17077\n\nInclusion Criteria:\n\n* Patient or legally authorized representative (LAR) provides authorization and\u002For consent per institution and geographical requirements\n* Patient has, or is intended to receive or be treated with, an eligible Medtronic product\n* Patient is consented within the enrollment window of the therapy received, as applicable\n* Patient is at least 18 years of age at time of enrollment.\n\nExclusion Criteria:\n\n* Patient who is, or is expected to be inaccessible for follow-up\n* Patient with exclusion criteria required by local law\n* Patient is currently enrolled in or plans to enroll in any concurrent drug and\u002For device study that may confound results\n* Female patient who is known to be pregnant or is breastfeeding or wishes to become pregnant during participation in the study.\n\nFor MDT24028 and MDT22032:\n\nGeneral Inclusion Criteria:\n\n* Patient or legally authorized representative (LAR) provides authorization and\u002For consent per institution and geographical requirements.\n* Patient is treated or intended to be treated with an eligible Medtronic Neurovascular product.\n* Patient is an adult per local law at time of consent. Medtronic Business Restricted This document is electronically controlled CONFIDENTIAL 056-F275 Rev F Clinical Investigation Plan Template\n\nGeneral Exclusion Criteria:\n\n* Patient who may be unable to complete the study follow-up\n* Patient with any contraindications per the applicable Instructions for Use document\n* Female patient who is known to be pregnant or is breastfeeding or wishes to become pregnant during participation in the study\n* Patient is currently enrolled in, or plans to enroll in, any concurrent drug\u002Fdevice study that may confound the study results.\n\nAdditional criteria may be required, refer to cohort-specific Addendum, as applicable, for further guidance.",{"count":113,"type":22},"5 Years","Post market surveillance registry",[147,29],"Intracranial Aneurysm",[149,150,151,152,153,154,155,156,157,158],"Embolization Device","Flow Diverter","Intrasaccular device","Vascular Reconstruction Device","Ruptured Intracranial Aneurysm","Unruptured Intracranial Aneurysm","Large Vessel Occlusion","Stent Retriever","Aspiration Catheter","Revascularization Device","2026-05-31",{"date":161,"type":43},"2026-06-02",{"date":163,"type":43},"2016-12",{"date":165,"type":22},"2032-08",{"name":167,"class":168},"Medtronic Neurovascular Clinical Affairs","INDUSTRY",99,{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":23,"phases":180,"briefSummary":181,"conditions":182,"keywords":193,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":218},"100635761","clinical-impact-of-using-improve-to-select-patients-for-carotid-revascularisation-100635761","NCT07556887","Clinical Impact of Using IMPROVE to Select Patients for Carotid Revascularisation","Clinical Impact of the Use of IMPROVE for Selection of Patients for Carotid Revascularisation: a Randomized Controlled Multicentre Non-inferiority Trial in Symptomatic Patients With 30-99% Carotid Stenosis","IMPROVE","Inclusion Criteria:\n\n* Mentally competent\n* 18 years or older\n* Recent (\\\u003C30 days) stroke (modified Rankin scale ≤3) or TIA\n* Ipsilateral 30-99% atheromatous stenosis at the carotid bifurcation assessed using non-invasive imaging according to NASCET criteria\n* Life expectancy \\>5 years\n* Patient and stenosis are suitable for carotid revascularisation\n* Patient is agreeable to randomisation and willing to accept either IMPROVE-based or CAU-based selection method for carotid revascularisation\n\nExclusion Criteria:\n\n* Cardiac source of embolism\n* Carotid stenosis caused by non-atherosclerotic disease e.g. dissection, fibromuscular disease or neck radiotherapy.\n* MRI contra-indications\n* Pregnancy",{"count":179,"type":22},613,[115],"Narrowing of the carotid artery due to atherosclerosis with an unstable plaque can cause a stroke. Patients with carotid artery disease who have had a TIA or minor stroke and are at high risk of another stroke are often treated with surgery or stenting to remove the plaque. For lower-risk patients, medication alone is the better option, as surgery also carries risks. A new decision method, based on MRI detection of unstable plaques (IMPROVE), can better assess stroke risk and help determine which patients do or do not need surgery. We are investigating whether this method is at least as effective as the standard approach, which mainly considers the degree of narrowing. We expect that this new method will help reduce strokes and lower healthcare costs.\n\nPatients will be followed for several years to compare which method is better for health and costs.",[183,184,185,186,187,188,189,190,191,192],"Carotid Artery Stenosis Symptomatic","Ischemic Cerebral Infarction","Stroke Ischemic","Atheroscleroses","Stroke (CVA) or TIA","Stroke","Intraplaque Hemorrhage","TIA (Transient Ischemic Attack)","Atherosclerosis Cerebral Infarction","Carotid Arteriosclerosis",[194,195,196,197,198,199,200,201,202,203,204,205,206,207,208],"Carotid Artery Stenosis","Transient Ischemic Attack","Ischemic Stroke","Atherosclerosis","Plaque Rupture","Revascularisation","Carotid Endarterectomy","Carotid Artery Stenting","Magnetic Resonance Imaging","Stroke Risk Prediction","Intraplaque hemorrhage","Clinical Decision Support","Randomized Controlled Mulitcentre Trial","Cost-Effectiveness Analysis","Optimal Medical Therapy","2026-05-12",{"date":211,"type":43},"2026-05-15",{"date":213,"type":43},"2026-03-31",{"date":215,"type":22},"2031-08-31",{"name":217,"class":50},"Maastricht University Medical Center",10,{"id":220,"slug":221,"hasResults":12,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":23,"phases":228,"briefSummary":229,"conditions":230,"keywords":232,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":245},"100527997","rescue-endovascular-therapy-for-progressive-acute-mild-ischemic-stroke-with-large-vascular-occlusion-100527997","NCT06155032","Rescue Endovascular Therapy for Progressive Acute Mild Ischemic Stroke With Large Vascular Occlusion","Study of Rescue Endovascular Therapy for Progressive Acute Mild Ischemic Stroke With Large Vascular Occlusion--- A Multi-centered, Prospective, Open-label, Blind Endpoint, Randomized Controlled Trial (RESCUE END-LOW)","Inclusion Criteria:\n\nGeneral Inclusion Criteria：\n\n* Age ≥ 18 years；\n* Presenting with symptoms consistent with an AIS and the initial NIHSS score \\\u003C6 points；\n* Symptom progression within 7 days of first onset；\n* Randomization can be finished \\> 24 hours of stroke onset (stroke onset time is defined as last known well time)；\n* Symptom progression to randomization time ≤ 24 hours；\n* NIHSS score before randomization ≥ 6 points；\n* Informed consent signed.\n\nSpecific Neuroimaging Inclusion Criteria\n\n* CTA or MRA proved occlusion of Internal Carotid Artery (ICA) terminal or M1 segment of Middle Cerebral Artery;\n* The progression of symptoms is caused by the recurrence of cerebrovascular diseases in the same vascular region, or the pathogenesis is caused by reduced blood flow perfusion;\n* NCCT ASPECTS before randomization ≥ 6\n* CTP or MRP assessment shows low perfusion in the target vessel area, and meets the following criteria: core infarction volume is less than 50ml, mismatch rate is greater than or equal to 1.8, and mismatch volume is greater than 15ml.\n\nExclusion Criteria:\n\n* Pre-stroke mRS score \\>1;\n* Imaging confirms the progression of symptoms caused by intracranial hemorrhage, brain edema, or other clear causes;\n* The target vessel may have factors that may prevent it from completing endovascular treatment, such as a diameter less than 1.5mm, a tortuous vascular pathway, difficulty in reaching the target position with instruments, or difficulty in recovery;\n* Severe stenosis or occlusion of multiple blood vessels;\n* Combined with untreated intracranial aneurysms, intracranial tumors (excluding small meningiomas), or intracranial vascular malformations;\n* Intracranial hemorrhage within 6 months, including cerebral parenchymal hemorrhage, ventricular hemorrhage, and subarachnoid hemorrhage;\n* Have had gastrointestinal or urinary system bleeding, acute myocardial infarction, traumatic brain injury, or undergone major surgical procedures within the past month;\n* Known hemorrhagic tendency (including but not limited to): Baseline platelet count \\\u003C40×109\u002FL; on anticoagulant therapy with warfarin and International Normalized Ratio (INR) \\> 2 (Patients with no history or suspected coagulopathy do not need to wait for laboratory results of INR or APTT prior to enrollment) Severe heart, liver, kidney function damage or other severe late stage diseases of the system;\n* Known allergies to treatment related drugs such as iodine contrast agents, etc; Known severe allergy (more than a rash) to contrast media uncontrolled by medications;\n* Refractory hypertension (defined as persistent systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg);\n* Uncontrolled blood sugar abnormalities (less than 2.8mmol\u002Fl or greater than 22.2mmol\u002Fl);\n* Females who are pregnant, or those of child-bearing potential with positive urine or serum beta Human Chorionic Gonadotropin (HCG) test;\n* The expected survival time is less than 1 year (such as complicated with malignant tumor, serious heart and lung diseases, etc.)\n* Participation in other interventional randomized clinical trials that may confound outcome assessment of the trial\n* Other circumstances that the investigator considers inappropriate for participation in the trial or that may pose significant risks to patients (such as inability to understand and\u002For follow the study procedures and\u002For follow up due to mental disorders, cognitive or emotional disorders)",{"count":227,"type":22},272,[115],"Endovascular therapy (EVT) added on best medical management is currently recommended in acute large vascular occlusion (LVO) stroke patients with National Institutes of Health Stroke Scale (NIHSS) score \\>5. Thus, a sizeable fraction of patients with a minor stroke that do not undergo cerebrovascular screening may experience an early neurological deterioration (END) due to LVO, possibly leading to poor long-term functional outcome. However, whether these patients may still benefit from a rescue EVT is unknown, especially in a late window (\\>24 hours). In this study, the investigators assume that best medical management plus EVT might be superior than best medical management alone in a late window for minor stroke patients who have experienced an LVO and END. The primary objective of the study was to establish the safety and efficacy of EVT in a late window for minor stroke patients in the anterior circulation who experienced an LVO and END.",[29,231],"Cerebrovascular; Disorder, Occlusive",[233,234,235],"endovascular therapy","mild stroke","neurological deterioration","2026-04-27",{"date":238,"type":43},"2026-04-30",{"date":240,"type":43},"2024-01-04",{"date":242,"type":22},"2027-03-30",{"name":244,"class":50},"First Affiliated Hospital of Wannan Medical College",7,{"id":247,"slug":248,"hasResults":12,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":252,"eligibilityCriteria":253,"healthyVolunteers":12,"sex":18,"minAge":254,"maxAge":4,"enrollmentInfo":255,"targetDuration":4,"studyType":23,"phases":257,"briefSummary":258,"conditions":259,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":51},"100529220","effect-of-remote-ischemic-preconditioning-on-collaterals-of-atherosclerosis-stroke-100529220","NCT06170944","Effect of Remote Ischemic Preconditioning on Collaterals of Atherosclerosis Stroke","Effect of Remote Ischemic Preconditioning on Collaterals of Atherosclerosis Stroke (RICAS): a Prospective, Randomized, Blind Endpoint, Multicenter Study","RICAS","Inclusion Criteria:\n\n* 1\\. Age over 40 years old;\n* 2\\. Diagnosed with ischemic stroke (including TIA and cerebral infarction), with onset time of more than 1 month;\n* 3\\. Culprit arteries are the large arteries of the anterior circulation with atherosclerotic stenosis (≥50%) or occlusion;\n* 4\\. ASITN\u002FSIR collateral circulation of 0-3 based on DSA evaluation;\n* 5\\. First onset or prior onset with no significant sequelae (mRS ≤ 2);\n* 6\\. Those who are not expected to undergo angioplasty within 12 months (judged by the doctor or decided by patients and\u002For their representatives);\n* 7\\. The availability of informed consent.\n\nExclusion Criteria:\n\n* 1\\) Patients with severe infection or serious diseases such as liver, kidney, hematopoietic system, endocrine system, etc.;\n* 2\\) Patients with a history of stroke and severe sequelae (mRS≥3);\n* 3\\) arterial stenosis due to aortic dissection, moyamoya disease; Any known vasculitic disease; herpes zoster, varicella-zoster or other viral infections with vascular lesions; neurosyphilis; other intracranial infections; any intracranial artery stenosis associated with hypercytosis of cerebrospinal fluid; radiation-induced vascular lesions; myofiber dysplasia; sickle cell disease; neurofibromas; benign vascular lesions of the central nervous system; postpartum vascular disease; stenosis of the intracranial arteries due to vasospasm or thrombosm;\n* 4\\) Uncontrolled severe hypertension (systolic pressure≥180mmHg or diastolic pressure≥110 mmHg after drug treatment) ;\n* 5\\) Subclavian artery stenosis ≥50% or subclavian artery steal syndrome;\n* 6\\) Patients with intracranial hemorrhage (parenchymal hemorrhage, subarachnoid hemorrhage, subdural\u002Fepidural hemorrhage) within 90 days before enrollment;\n* 7\\) Intracranial tumor, arteriovenous malformation, or aneurysm;\n* 8\\) Patients with severe hematologic diseases or severe coagulation abnormalities;\n* 9\\) Retinal hemorrhage or visceral hemorrhage within 30 days;\n* 10\\) Those who are expected to undergo major surgery (including femoral artery, cardiac, aortic or carotid artery surgery) within 30 days before enrollment or within 12 months after enrollment;\n* 11\\) Those who have received stent implantation, angioplasty or other related medical devices for the target diseased blood vessels, or those who are expected to undergo the above treatments within 12 months after enrollment;\n* 12\\) Any contraindication for remote ischemic adaptation: the upper limb has serious soft tissue injury, fracture or vascular injury, distal upper limb perivascular lesions, etc.\n* 13\\) Damage and lesions in the cerebral veins;\n* 14\\) Pregnant or lactating women;\n* 15\\) Those who are participating in other clinical trials within 3 months;\n* 16\\) Life expectancy is less than 1 year\n* 17\\) Patients not suitable for this clinical studies considered by researcher","40 Years",{"count":256,"type":22},300,[115],"The goal of this clinical trial is to explore the influence of chronic RIC on collateral status evaluated by DSA in ischemic stroke patients with LAA etiology.",[29],"2026-04-22",{"date":236,"type":43},{"date":263,"type":43},"2024-06-01",{"date":265,"type":22},"2027-11-30",{"name":267,"class":50},"General Hospital of Shenyang Military Region",{"id":269,"slug":270,"hasResults":12,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":274,"eligibilityCriteria":275,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":276,"enrollmentInfo":277,"targetDuration":4,"studyType":23,"phases":279,"briefSummary":280,"conditions":281,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":283,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":287,"locationsCount":51},"100343585","phase-4-the-effect-of-intensive-statin-in-ischemic-stroke-with-intracranial-atherosclerotic-plaques-100343585","NCT03753555","The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques","The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques: a Prospective, Random, Single-center Study Based on High Resolution Magnetic Resonance Imaging","INSIST-HRMRI","Inclusion Criteria:\n\n1. Patient age between 18-80 years\n2. Time of onset: within 1 week\n3. NIHSS score ≤12\n4. Acute ischemic stroke confirmed by head CT or MRI\n5. Premorbid mRS ≤1\n6. The degree of stenosis of carotid artery, vertebral artery and intracranial portion of internal carotid artery on the lesion side \\\u003C50%\n7. The culprit plaque or possible culprit plaque with plaque burden of 40% or more found by HRMRI in the proximal part of the middle cerebral artery M1 segment or basilar artery of ipsilateral lesion\n8. Signed informed consent\n\nExclusion Criteria:\n\n1. Intracranial hemorrhage found by head CT\n2. Stroke attributable to cardioembolic origin (atrial fibrillation, valvular heart disease, aortic arch atherosclerosis)\n3. Severe hepatic or renal dysfunction\n4. Pregnant females\n5. Abnormal elevation of creatine phosphokinase\n6. Expected stent angioplasty\n7. Blood sugar is out of control\n8. Receiving statins within 1 month before onset\n9. Obstinate hypertension with more than 140\u002F90 mmHg after medication\n10. Not willing and able to comply with scheduled visits, lifestyle guidelines, treatment plan, laboratory tests, and other study procedures\n11. Unsuitable for this clinical studies assessed by researcher","80 Years",{"count":278,"type":22},100,[25],"Intracranial atherosclerotic disease is the most common cause of ischemic stroke that is directly attributed to the progression or rupture of intracranial high-risk plaque in Asia. Many studies mainly from Euro-American population with a focus on extracranial carotid plaque have fully demonstrated the advantages of intensive statin therapy on stabilizing or reversing plaque burden, reversing plaque composition presenting that lipid-rich necrotic core (LRNC) is gradually replaced by fibrous tissue, and even reversing pattern of arterial remodeling to reduce the occurrence of cerebrovascular events. Yet, direct evidence of the effect of intensive statin therapy on intracranial atherosclerotic plaques is lacking and the effect of statin intensity and duration on intracranial plaque burden and composition is still unclear. High resolution magnetic resonance imaging (HRMRI) is a new and non-invasive technique that enable to assess the morphologic characteristics of vascular wall and plaque composition of intracranial artery. Based on above discussion, the investigators conduct this study to further determine the effect of intensive statin in ischemic stroke with intracranial atherosclerotic plaques.",[29,282],"Atherosclerosis, Cerebral",{"date":236,"type":43},{"date":285,"type":43},"2018-12-01",{"date":265,"type":22},{"name":267,"class":50},{"id":289,"slug":290,"hasResults":12,"nctId":291,"briefTitle":292,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":295,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":297,"conditions":298,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":7},"100509295","treatment-with-endovascular-intervention-for-stroke-patients-with-existing-disability-100509295","NCT05911568","Treatment With Endovascular Intervention for STroke Patients With Existing Disability","TESTED","Inclusion Criteria:\n\n1. Adult patients (≥18 years)\n2. Moderate-to-severe pre-stroke functional disability, defined as mRS 3-4, for at least 3 months prior to stroke onset\n3. Presenting to study hospital within 24 hours of last known well time\n4. Diagnosis of acute ischemic stroke\n5. Intracranial causative occlusion of the internal carotid artery or the M1 or dominant M2 segments of the middle cerebral artery visualized on the baseline CT(or MR) angiogram\n6. Presenting CT Alberta Stroke Program Early CT (ASPECT) score ≥3 or MRI ASPECT score ≥4\n7. Presenting NIH Stroke Scale score ≥6\n8. Informed consent from patient if competent or from legally authorized representative\n\nExclusion Criteria:\n\n1. Known diagnosis of a terminal cancer or terminal illness at the time of stroke\n2. Assessment of pre-stroke functional status cannot be performed during the hospital stay\n3. Pre-stroke disability deemed temporary in the investigator's opinion (for example, recovering from a general medical illness or traumatic bodily injury)",{"count":296,"type":22},1060,"TESTED will compare the risks and benefits of endovascular thrombectomy (EVT) to medical management (no EVT) in ischemic stroke patients who have a blockage in one of the large blood vessels in the brain and have a moderate-to-severe disability prior to their stroke.",[188,65,29],"2026-04-14",{"date":301,"type":43},"2026-04-15",{"date":303,"type":43},"2023-11-16",{"date":305,"type":22},"2028-04-15",{"name":307,"class":50},"University of Cincinnati",{"id":309,"slug":310,"hasResults":12,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":314,"eligibilityCriteria":315,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":316,"targetDuration":4,"studyType":23,"phases":318,"briefSummary":319,"conditions":320,"keywords":323,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":51},"100566670","phase-3-efficacy-and-safety-of-tenecteplase-bridging-mechanical-thrombectomy-for-acute-large-vessel-occlusion-stroke-100566670","NCT06658197","Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke","Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusive Stroke(TNK-LVO) :a Phase 3, Multicentre, Open-label, Randomised Controlled Trial","TNK-LVO","Inclusion Criteria:\n\n1. Age is ≥18 years.\n2. AIS symptom onset ≤4.5 hours, onset time refers to the time the patient was last known to be well. (Recommendation time from thrombolysis to puncture within 60 minutes).\n3. Arterial occlusion of the internal carotid artery (ICA), anterior cerebral artery (ACA), posterior cerebral artery (PCA), M1 or M2 segment of the middle cerebral artery (MCA), or basilar artery on computed tomography angiography (CTA) or magnetic resonance angiography (MRA).\n4. Prestroke mRS score ≤2.\n5. Informed consent from the patient or legally authorised representative.\n\nExclusion Criteria:\n\n1. Patients diagnosed with hemorrhagic stroke (including intraparenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural\u002Fextradural hematoma, etc.) or other related conditions identified by CT.\n2. Contraindication to imaging examinations involving contrast agent injection.\n3. Patients presenting with clinical symptoms of coma (NIHSS Score Item 1a = 3).\n4. History of intracranial hemorrhage.\n5. History of severe head trauma or stroke within the past 3 months.\n6. Intracranial or intraspinal surgery within the past 3 months.\n7. Major surgery within the past 2 weeks.\n8. Gastrointestinal or urinary tract bleeding within the past 3 weeks.\n9. Intracranial tumor, arteriovenous malformation, or giant intracranial aneurysm.\n10. Active visceral bleeding.\n11. Aortic arch dissection.\n12. Arterial puncture at a non-compressible site within the past week.\n13. Uncontrolled hypertension despite active antihypertensive treatment: Systolic Blood Pressure \\> 180 mmHg or Diastolic Blood Pressure \\> 100 mmHg.\n14. Acute hemorrhagic tendency, including platelet count \\\u003C 100 × 10⁹\u002FL or other conditions.\n15. Heparin treatment received within the past 24 hours.\n16. For patients on oral anticoagulants: INR \\> 1.7 or PT \\> 15 seconds.\n17. Use of direct thrombin inhibitors or direct Factor Xa inhibitors within the past 48 hours.\n18. Blood glucose \\\u003C 2.8 mmol\u002FL or \\> 22.2 mmol\u002FL.\n19. Hypodensity affecting \\> 1\u002F3 of the middle cerebral artery territory or an equivalent proportion of the basilar artery territory on non-contrast CT.\n20. Rapidly improving symptoms as determined by the investigator.\n21. Participation as a subject in another research study within the past 30 days.\n22. Any terminal illness where life expectancy is considered not to exceed 1 year.\n23. Any condition where, in the judgment of the investigator, the study treatment might pose a risk to the patient or affect the patient's participation in the study.\n24. Pregnant women.\n25. Known allergy to the active ingredients (Alteplase, Tenecteplase) or any excipients.",{"count":317,"type":22},850,[62],"A phase III, multicentre, prospective, randomised, open-label, blinded-endpoint clinical trial will evaluate two thrombolytic agents for the treatment of acute large vessel occlusion stroke within 4.5 hours from symptoms onset: intravenous tenecteplase bridging mechanical thrombectomy vs. intravenous alteplase bridging mechanical thrombectomy.",[29,65,321,322],"Thrombosis, Brain","Drug Effect",[324,325],"Ischemic stroke","Tenecteplase","2026-04-08",{"date":328,"type":43},"2026-04-09",{"date":330,"type":43},"2025-12-25",{"date":332,"type":22},"2027-06-01",{"name":334,"class":50},"Xuanwu Hospital, Beijing",{"id":336,"slug":337,"hasResults":12,"nctId":338,"briefTitle":339,"officialTitle":339,"acronym":340,"eligibilityCriteria":341,"healthyVolunteers":12,"sex":18,"minAge":342,"maxAge":343,"enrollmentInfo":344,"targetDuration":4,"studyType":23,"phases":346,"briefSummary":347,"conditions":348,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":51},"100554991","motor-recovery-through-plasticity-inducing-cortical-stimulation-100554991","NCT06506279","Motor Recovery Through Plasticity-Inducing Cortical Stimulation","MRPICS","Inclusion Criteria:\n\n22-75 years of age\n\n* History of ischemic stroke\n* Minimum 6 months post-ischemic cortical stroke\n* Levels of hemiparesis that warrant surgical intervention (upper limb impairment)\n* Able to participate in a meaningful way in rehabilitation (defined by upper extremity Fugl-Myer (UEFM) score of 25-45\n* Disability measured between 3 and 4 on the modified Rankin Scale\n* Minimum of 30% preservation of the corticospinal pathways in MRI imaging\n* Observable motor output of the upper limb in response to TMS delivered to the motor cortex\n* Available for the duration of the study, 54 weeks for multiple visits (38 weeks implanted and 16 weeks post-explant follow-up).\n* All inclusion and exclusion criteria will be assessed within 90 days before the device implantation procedure (though the PI may determine to override the 90-day limit for MRI imaging results review).\n\nExclusion Criteria:\n\n* Unable to discontinue anti-platelet medication for 7 days pre- and 3 days post-op\n* On therapeutic anticoagulation\n* A history of unprovoked deep vein thrombosis or any pulmonary embolus\n* The presence of a bleeding disorder which significantly increases the chances that the patient will have a hemorrhagic complication in relation to study procedures.\n* Other medical history indicating increased risk of thrombosis per investigator discretion\n* Any history of seizures\n* Pregnancy\n* Geriatric Depression Score greater than 10\n* Montreal Cognitive Assessment below 22 unless attributable to aphasia and approved by PI\n* Columbia Suicide Scale ideation score above 1\n* Aphasia or cognitive deficits substantial enough to prevent:\n\n  * communication of pain and discomfort due to study procedures\n  * understanding of motor testing or rehabilitation tasks\n* Severe Neglect as measured by NIH Stroke Scale Question 11 score of 2, which represents a \"Profound hemi-inattention or extinction to more than one modality; does not recognize own hand or orients to only one side of space.\"\n* Cardiac morbidity that in the judgment of the investigators would represent an increased safety risk\n* History of spontaneous hemorrhagic stroke\n* Major, active neurological, psychiatric, or medical comorbidity that would likely interfere with study procedures\n* Any active infection requiring antimicrobial therapy\n* Inability to participate with proposed rehabilitation strategies\n* Presence of any other implanted devices (cochlear implants, pacemakers, etc.).\n* During this study no occupational, physical, or speech therapy is permitted apart from that provided by the study protocol. Patients who require therapy beyond what is delivered in this study will not be enrolled\n* All inclusion and exclusion criteria will be assessed within 90 days before the device implantation procedure (though the PI may determine to override the 90-day limit for MRI imaging results review).\n\nIf a patient has glenohumeral subluxation, adhesive capsulitis, or contractures of the upper extremities, they must undergo additional screening for pain with range-of-motion and be approved by the enrolling clinician.\n\nIf a patient requires any medication not already explicitly excluded as part of defined safety criteria, the clinical staff affiliated with this study will determine if the patient should be excluded at their own discretion to ensure the integrity of this study.\n\n\\-","22 Years","75 Years",{"count":345,"type":22},4,[115],"Using the CorTec Brain Interchange (BIC) System, we will examine the effect of a plasticity-inducing therapy regime on the rehabilitation of upper limb impairment post-stroke. This study's main objective is to implement and evaluate neuroplasticity-inducing stimulation. The stimulation methods for inducing neuroplasticity have been selected based on prior preclinical and intraoperative work that has shown promise in providing rehabilitative benefits for stroke patients. We will be structuring this study as an open prospective feasibility study.",[29],"2026-04-07",{"date":351,"type":43},"2026-04-13",{"date":353,"type":43},"2025-07-22",{"date":355,"type":22},"2030-06-15",{"name":357,"class":50},"University of Washington",{"id":359,"slug":360,"hasResults":12,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":366,"enrollmentInfo":367,"targetDuration":368,"studyType":86,"phases":4,"briefSummary":369,"conditions":370,"keywords":372,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":51},"100380222","circulating-non-coding-rna-in-acute-ischemic-stroke-with-endovascular-treatment-evtrna-100380222","NCT04230785","Circulating Non-coding RNA in Acute Ischemic Stroke With Endovascular Treatment (EVTRNA)","Clinical Significance of Circulating Non-coding RNA in Acute Ischemic Stroke With Endovascular Treatment (EVTRNA)","EVTRNA","Inclusion Criteria:\n\n* Aged 18 years or older\n* Confirmed acute ischemic stroke by a diffusion-weighted imaging-position lesion on magnetic resonance imaging (MRI) and a new lesion on a brain computed tomography (CT) scan\n* Within 24 hours of symptom onset and treat with endovascular therapy\n* Good performance status\n* Signed an approved informed consents\n\nExclusion Criteria:\n\n* a history of hemorrhagic infarction, chronic kidney\u002Fliver diseases, peripheral arterial occlusive disease, active malignant disease, and inflammatory or infectious diseases","90 Years",{"count":256,"type":22},"90 Days","EVTRNA is to analyze the differentiated expression pattern of circular RNA (circRNA), long non-coding RNA (lncRNA) and micro-RNA (miRNA) by next-generation sequencing in acute ischemic stroke patients before and\u002For after endovascular treatment. The candidate circRNA\u002FlncRNA\u002FmiRNA will be verified as the biomarker and regulator for progression and prognosis of acute ischemic stroke with endovascular treatment. Further, the candidate non-coding RNA will be used to evaluate the effect of endovascular treatment on both peripheral and central immune after stroke.",[65,29,371],"Endovascular Treatment",[373,374,375,376,377],"acute ischemic stroke","noncoding RNA","endovascular treatment","clinical significance","outcome","2026-04-06",{"date":328,"type":43},{"date":381,"type":43},"2020-03-15",{"date":383,"type":22},"2026-12-01",{"name":385,"class":50},"Nanjing First Hospital, Nanjing Medical University",{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":390,"acronym":391,"eligibilityCriteria":392,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":393,"targetDuration":4,"studyType":23,"phases":395,"briefSummary":396,"conditions":397,"keywords":399,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":411,"locationsCount":245},"100596557","phase-3-advancing-reperfusion-therapy-for-ischemic-stroke-arts-tenecteplase-in-medium-vessel-occlusion-mevo-for-acute-ischemic-stroke-100596557","NCT07047014","Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic Stroke","ARTS-MeVO","Inclusion Criteria:\n\n* (1)Age≥18 years old;\n* (2)Acute ischemic stroke symptom onset within 4.5 - 24 hours; including wake-up stroke and unwitnessed stroke, onset time refers to \"last-seen normal time\";\n* (3)Primary medium vessel occlusions confirmed by CTA\u002FMRA, including distal M2\u002FM3 segments of the middle cerebral artery (MCA), A1\u002FA2\u002FA3 segments of the anterior cerebral artery (ACA), and P1\u002FP2\u002FP3 segments of the posterior cerebral artery (PCA) and responsible for the signs and symptoms of acute ischemic stroke;\n* (4)Neuroimaging criteria: a) Perfusion criteria:Target mismatch profile on CT perfusion or MRI+MR perfusion (ischemic core volume \\\u003C70mL, mismatch ratio \\>1.2, mismatch volume \\>10mL); b) If neither MRI or CT perfusion is available at the site : an Alberta Stroke Program Early CT Score \\[ASPECTS\\] of 8 or more on NCCT \u002FMRI-DWI or PC-ASPECTS of 8 or more on NCCT\u002FMRI-DWI.\n* (5)Pre-stroke modified Rankin scale (mRS) score ≤1;\n* (6)Baseline National Institutes of Health Stroke Scale (NIHSS) ≥6 or NIHSS 3-5 with disabling symptoms;\n* (7)Written informed consent from patients or their legally authorized representatives.\n\nExclusion Criteria:\n\n* (1)Allergy to tenecteplase;\n* (2)Rapidly improving symptoms at the discretion of the investigator;\n* (3)NIHSS consciousness score 1a \\>2, or epileptic seizure, hemiplegia after seizures (Todd's palsy) or other neurological\u002Fmental illness such that the patient is not able to cooperate or unwilling to cooperate;\n* (4)Intention to undergo endovascular treatment.\n* (5)Persistent blood pressure elevation (systolic ≥185 mmHg or diastolic ≥110 mmHg), despite blood pressure-lowering treatment;\n* (6)Blood glucose \\\u003C2.8 or \\>22.2 mmol\u002FL (point of care glucose testing is acceptable);\n* (7) Active internal bleeding or at high risk of bleeding, e.g., major surgery, trauma or gastrointestinal or urinary tract hemorrhage within the previous 21 days, or arterial puncture at a non-compressible site within the previous 7 days;\n* (8)Any known impairment in coagulation due to comorbid disease or anticoagulant use. If on warfarin, then INR \\>1.7 or prothrombin time \\>15 seconds; use of any direct thrombin inhibitors or direct factor Xa inhibitors during the last 48 hours unless reversal of dabigatran can be achieved with idarucizumab; any full dose heparin\u002Fheparinoid during the last 24 hours or with an APTT greater than the upper limit of normal;\n* (9)Known defect of platelet function or platelet count below 100,000\u002Fmm3 (NB patients taking antiplatelet medication can be included);\n* (10)Ischemic stroke or myocardial infarction in previous 3 months, previous intracranial hemorrhage, severe traumatic brain injury or intracranial or intraspinal operation in previous 3 months, or known intracranial neoplasm, arteriovenous malformation, or giant aneurysm;\n* (11)Any terminal illness such that the patient would not be expected to survive more than 1 year;\n* (12) Unable to perform CTP or PWI;\n* (13)Hypodensity in \\>1\u002F3 MCA territory on non-contrast CT or hypodensity outside the current perfusion lesion suggesting distal clot migration (secondary MeVO);\n* (14)Acute or past intracerebral hemorrhage (ICH) identified by CT or MRI;\n* (15)Pregnant women, nursing mothers, or reluctance to use effective contraceptive measures during the period of the trial;\n* (16)Unlikely to adhere to the trial protocol or follow-up;\n* (17) Participation in other interventional clinical trials within the previous 3 months.",{"count":394,"type":22},596,[62],"Results from recent several trials provided data showing limits to the effectiveness of thrombectomy for ischemic stroke due to medium vessel occlusions.The benefit-risk profile of thrombolysis for these patients has never been investigated. We initiated a multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled trial to evaluate the efficacy and safety of tenecteplase (0.25mg\u002Fkg, maximum dose 25mg) compared to standard medical care for patients with acute ischemic stroke due to medium vessel occlusion (MeVO) within 4.5 to 24 hours from symptom onset.",[29,398],"Medium Vessel Occlusions",[400,401,402,403],"ischemic stroke","tenecteplase","medium vessel occlusions","beyond 4.5 hours","2026-03-27",{"date":406,"type":43},"2026-04-01",{"date":408,"type":43},"2025-07-30",{"date":410,"type":22},"2027-06-30",{"name":412,"class":50},"Beijing Tiantan Hospital",{"id":414,"slug":415,"hasResults":12,"nctId":416,"briefTitle":417,"officialTitle":417,"acronym":4,"eligibilityCriteria":418,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":343,"enrollmentInfo":419,"targetDuration":4,"studyType":23,"phases":421,"briefSummary":422,"conditions":423,"keywords":425,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":51},"100462590","effects-of-neuronavigated-theta-burst-stimulation-in-therapy-of-post-stroke-aphasia-100462590","NCT05303649","Effects of Neuronavigated Theta Burst Stimulation in Therapy of Post-stroke Aphasia","Inclusion Criteria:\n\n* First-ever left middle cerebral artery ischemic stroke (brain damage localization confirmed by magnetic resonance imaging, MRI)\n* 3 or more months from the onset of stroke\n* Non-fluent aphasia (confirmed in the BDAE test) with functional communication difficulties ranging from mild to significant (grades from 2 to 4 in ASRS), marked difficulties in naming, and relatively preserved everyday speech comprehension\n* Native Polish speaker\n* Right-handedness prior to stroke\n* Signing of the informed consent for the participation in the study.\n\nExclusion Criteria:\n\n* Psychiatric and\u002For neurological comorbidity (e. g. dementia, depressive disorder, alcohol dependence)\n* Diagnose of epilepsy or epileptic changes in EEG, also frequent losses of consciousness of unclear etiology which might suggest epileptic seizures\n* History of any neurosurgical procedure around the head area\n* 1.5 T MRI examination contraindications (metal elements in the body, e. g. implantable cardioverter-defibrillator, deep brain stimulation devices; claustrophobia)\n* Regular intake of medication that could affect cortical excitability (e. g. antiepileptic or antipsychotic drugs, antidepressants, benzodiazepines) or medication influencing neuroplastic processes (e. g. dopamine)\n* Significant cognitive impairment limiting patient's cooperation during assessment and behavioral aphasia therapy\n* Visual deficits significantly hindering the perception of therapeutic tasks presented visually on a computer's screen\n* New neurological episode (e. g. another brain stroke) or somatic illness (e. g. COVID-19) during the cycle of the therapy, requiring its interruption.",{"count":420,"type":22},45,[115],"Aphasia is an impairment in the ability to express and\u002For understand language, commonly observed after stroke to the language dominant (left) hemisphere. Despite natural tendency to spontaneous functional recovery in the first months post stroke and language improvement due to application of behavioral speech and language therapy (SLT), many aphasic patients do not achieve satisfactory level of verbal communication. The aim of the planned study is to explore the potential of the noninvasive repetitive Transcranial Magnetic Stimulation (rTMS) as a therapeutic tool for aphasia in addition to traditional behavioral therapy. In case of aphasia, studies on therapeutic effectiveness of rTMS aim to increase the activity of the language-dominant left cerebral hemisphere, which may be achieved in an indirect manner by inhibiting the activity of the opposite (right) hemisphere or in a direct manner by increasing the excitability of preserved language areas in the left hemisphere. In our study, we plan to administer the newest form of rTMS called Theta Burst Stimulation (TBS), which is safer than the conventional rTMS, even when used in the perilesional area. Computer-based neuronavigation system will be implemented to precisely localize stimulation targets, control administration of stimuli during rTMS sessions, and evaluate differences between participants regarding deviations from established stimulation points. 45 patients (all right-handed, polish native speakers, aged 18-75 years, diagnosed with non-fluent aphasia) will be enrolled in a randomized, double-blind, sham-controlled trial. Subjects will be randomly assigned to one of the three groups: 1) a group with excitatory intermittent TBS of the left hemisphere (iTBS group), 2) a group with inhibitory continuous TBS of the right hemisphere (cTBS group), 3) a group with sham TBS (sTBS group as a control group). Specific forms of stimulation will be carried out for three consecutive weeks (Monday to Friday; a total of 15 stimulation sessions). Immediately after each session of the stimulation, patients will undergo individual SLT. Assessment of language functioning will be carried out three times: before and after the therapy period, and 3 months after its completion. Results of the study will broaden knowledge about hemispherical mechanisms of language and speech recovery after stroke and provide insight into possibilities of their modulation for the purpose of post-stroke rehabilitation.",[29,424],"Aphasia Non Fluent",[426,188,427,428,429,430],"Aphasia","Theta Burst Stimulation","Therapy","Rehabilitation","Noninvasive Transcranial Brain Stimulation","2026-03-26",{"date":213,"type":43},{"date":434,"type":43},"2022-09-02",{"date":436,"type":22},"2027-12",{"name":438,"class":50},"Institute of Psychiatry and Neurology, Warsaw",{"id":440,"slug":441,"hasResults":12,"nctId":442,"briefTitle":443,"officialTitle":443,"acronym":444,"eligibilityCriteria":445,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":446,"enrollmentInfo":447,"targetDuration":4,"studyType":23,"phases":448,"briefSummary":450,"conditions":451,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":459,"locationsCount":51},"100450027","phase-2-promoting-recovery-after-stroke-with-amantadine-100450027","NCT05140148","Promoting Recovery After STroke With Amantadine","PRESTA","Inclusion Criteria:\n\n1. 18 to 85 years old, male and female\n2. Modified Rankin Score (mRS)\\\u003C=2 prior to stroke\n3. Ischemic or hemorrhagic stroke as diagnosed by vascular neurologist or as proven on magnetic resonance imaging (MRI) or non-contrast head computed tomography NCHCT)\n4. 24 hours to 3 weeks after stroke onset or time last known well prior to detection of symptoms\n5. National Institute of Health Stroke Scale (NIHSS)\\>=3 and NIHSS\\\u003C=15\n6. Creatinine Clearance of greater than or equal to 60 mL\u002Fmin using the Cockroft- Gault equation.\n7. Have passed a swallow evaluation prior to drug administration\n8. The patient is an acute rehabilitation candidate or candidate for the Homeward Stroke Program\n9. Able to participate in administered tests\n\nExclusion Criteria:\n\n1. Any degree of receptive aphasia\n2. Moderate or severe expressive aphasia\n3. Currently pregnant or plans to get pregnant\n4. Currently breastfeeding\n5. Any patient admitted with primary SubarachnoidH emorrhage (SAH )on either non-contrast head CT or MRI brain\n6. Diagnosis of dementia or mild cognitive impairment prior to index stroke\n7. Prior limb amputation\n8. Currently prescribed or taking a primary anticholinergic medication\n9. Currently enrolled in any other investigational pharmacologic or procedural clinical trial\n10. Malignancy with active treatment\n11. History of prior stroke with residual impairment\n12. Current or prior neuroleptic use\n13. History of suicidality or psychosis (The Columbia Suicide Severity Ratings Scale (C-SSRS) will be administered at the screening visit to assess depression and suicidal thoughts for subject eligibility. Any subjects who indicate severe depression or suicidal thoughts and\u002For attempts within the last year will not be eligible)\n14. Prior history of seizures\n15. Prior treatment with amantadine\n16. Parkinson's disease\n17. Amantadine allergy\n18. Elevated liver function tests (aspartate aminotransferase and alanine aminotransferase above the upper limit of normal) -","85 Years",{"count":21,"type":22},[449],"PHASE2","The investigators aim to examine whether amantadine can help patients recover from stroke. This will be a blinded randomized clinical trial (RCT). Patients will be randomized post-ischemic or hemorrhagic stroke either to the placebo arm or amantadine arm. Patients will be on study drug or placebo for 1 month but will be enrolled for 3 months total. At various time points patients will be examined and fill out questionnaires to determine level of stroke recovery.",[29,30],"2026-03-25",{"date":454,"type":43},"2026-03-30",{"date":456,"type":43},"2022-02-01",{"date":458,"type":22},"2028-06-30",{"name":460,"class":50},"University of Pennsylvania",{"id":462,"slug":463,"hasResults":12,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":4,"eligibilityCriteria":467,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":276,"enrollmentInfo":468,"targetDuration":4,"studyType":23,"phases":470,"briefSummary":471,"conditions":472,"keywords":474,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":481,"startDateStruct":482,"completionDateStruct":484,"leadSponsor":486,"locationsCount":51},"100628078","hiit-vs-mcit-for-stroke-related-sarcopenia-in-ischemic-stroke-100628078","NCT07456956","HIIT vs MCIT for Stroke-Related Sarcopenia in Ischemic Stroke","The Effect of High-Intensity Interval Training Versus Moderate-Intensity Continuous Training on Sarcopenia and Clinical Outcomes in Patients With Ischemic Stroke: A Single-Blind Randomized Controlled Trial","Inclusion Criteria:\n\n* First-ever stroke.\n* Age 18 years or older.\n* Diagnosis of ischemic stroke.\n* Stroke duration between 1-6 months (subacute phase).\n* Modified Rankin Scale score \\\u003C 3.\n* Mini-Mental State Examination (MMSE) score ≥ 24.\n* Brunnstrom lower extremity motor stage between Stage III-V.\n* Lower extremity functional capacity sufficient to allow exercise participation (able to ambulate at least with an assistive device).\n* Lower extremity spasticity ≤ 2 according to the Modified Ashworth Scale.\n* Independent sitting balance (able to sit unsupported for at least 30 seconds).\n* Presence of sufficient voluntary active movement in the lower extremity to permit exercise application.\n* Ability to communicate.\n* Willingness to participate in the study and provision of written informed consent.\n\nExclusion Criteria:\n\n* Presence of hemispatial neglect.\n* History of recurrent stroke.\n* Presence of a psychiatric disorder.\n* Presence of orthopedic, neurological, or cardiopulmonary conditions that would contraindicate the planned exercise protocols.",{"count":469,"type":22},32,[115],"The aim of this study is to investigate the effect of post-stroke sarcopenia on prognosis and clinical outcomes in patients with ischemic stroke and to compare the effects of High Intensity Interval Training (HIIT) and Moderate Intensity Continuous Training (MCIT) exercise programs on muscle mass, as well as on functional capacity, quality of life, and clinical outcomes.",[29,473],"Sarcopenia",[196,475,476,477,478,479],"Stroke-Related Sarcopenia","HIIT","MCIT","Exercise Training","Muscle Thickness","2026-03-22",{"date":452,"type":43},{"date":483,"type":43},"2026-03-02",{"date":485,"type":22},"2027-06-06",{"name":487,"class":50},"Fenerbahce University",{"id":489,"slug":490,"hasResults":12,"nctId":491,"briefTitle":492,"officialTitle":493,"acronym":494,"eligibilityCriteria":495,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":496,"enrollmentInfo":497,"targetDuration":4,"studyType":23,"phases":499,"briefSummary":500,"conditions":501,"keywords":503,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":511,"locationsCount":513},"100388580","noblestitch-el-stitch-trial-is-a-pfo-comparative-trial-100388580","NCT04339699","NobleStitch EL STITCH Trial is a PFO Comparative Trial","STITCH - Prospective Multi Center Comparative Parallel Concurrent Study of the NobleStitch EL Compared to FDA Approved Amplatzer Occluder Device for Closure of Patent Foramen Ovale to Prevent Recurrent Ischemic Stroke","STITCH","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female ages 18 - 60 years old\n* A PFO and a Cryptogenic Stroke verified by a neurologist\n* Stroke is defined as an acute focal neurological deficit, presumed to be due to focal ischemia, and either:\n\n  * Symptoms persisting ≥24 hours, or\n  * Symptoms persisting \\\u003C24 hours with Magnetic Resonance or CT findings of a new, neuroanatomical relevant infarct\n* Cryptogenic stroke was defined as a stroke of unknown cause\n* Prolonged cardiac rhythm monitoring (recommended 30 days and not less than 24 hours required)\n* Intra and extracranial artery imaging: Magnetic Resonance Angiography, CT angiography, or contrast angiography, or contrast angiography or echocardiography of the carotid arteries to rule out ischemic stroke associated with atherosclerotic plaque, arterial dissection, or other vascular diseases. (The aortic arch may also be evaluated by TEE).\n* Hypercoagulable state assessment to rule out an underlying hypercoagulable state\n\nExclusion Criteria:\n\n* Female participant who is pregnant, lactating or planning a pregnancy during the course of the study\n* Age \\\u003C18 or \\> 60 years of age\n* Previous myocardial infarction or unstable angina within 6 months\n* Clinically significant mitral or aortic valve stenosis or severe regurgitation\n* Left Ventricular Ejection Fraction \\\u003C50 percent\n* Progressive neurological dysfunction or reduced life expectancy\n* Contrast allergy\n* Atrial Septal Defect (baseline left to right shunt assessed by TEE or other congenital heart diseases\n* Active Endocarditis\n* Perspective participants with known causes of Ischemic Stroke\n* Arterial dissection\n* Contraindicated or unsuitable for antiplatelet agents or oral anticoagulants\n* Perspective participants with prosthetic heart valves\n* Uncontrolled diabetes Mellitus\n* Pulmonary hypertension\n* Uncontrolled systemic hypertension\n* Intracranial pathology\n* Neurological deficits not due to stroke that may affect neurologic assessments\n* Active autoimmune disease\n* Active infection\n* Alcohol and\u002For drug abuse\n* A requirement for chronic anticoagulation therapy that cannot be discontinued\n* Anatomic features (inability to achieve vascular access)","60 Years",{"count":498,"type":22},640,[115],"STITCH - Prospective Multi-Center Comparative Parallel Concurrent Study of the NobleStitch™ EL versus FDA-approved Amplatzer Occluder device for closure of Patent Foramen Ovale to prevent recurrent Ischemic stroke.",[502,29],"Foramen Ovale, Patent",[504,188],"Patent Foramen Ovale","2026-03-18",{"date":507,"type":43},"2026-03-23",{"date":509,"type":43},"2021-01-01",{"date":410,"type":22},{"name":512,"class":168},"Nobles Medical Technologies II Inc",2,{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":4,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":521,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":523,"conditions":524,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":527,"lastUpdatePostDateStruct":528,"startDateStruct":529,"completionDateStruct":531,"leadSponsor":533,"locationsCount":535},"100483689","effective-translation-of-endovascular-thrombectomy-trials-into-real-world-practice-in-the-asia-pacific-100483689","NCT05578300","Effective Translation of Endovascular Thrombectomy Trials Into Real-world Practice in the Asia-Pacific","Effective Translation of Endovascular Thrombectomy Trials Into Real-world Practice in the Asia-Pacific: a Multicenter, Prospective Registry (ENDURE-APAC)","Inclusion Criteria:\n\n* Patient who are over 18 years of age.\n* Patient with ischemic stroke with suspected large vessel occlusion (LVO), defined as occlusion of the internal carotid artery (ICA), M1 or M2 segment of the middle cerebral artery (MCA), or basilar artery (BA).\n\nExclusion Criteria:\n\n* Patient with isolated vertebral artery occlusion not involving the BA.",{"count":522,"type":22},350,"As a major breakthrough of acute stroke treatment over the past decade, endovascular thrombectomy (EVT) drastically improved neurological recovery and survival in patients with large vessel occlusion (LVO) ischemic strokes in major clinical trials. Nevertheless, much remained uncertain about the implementation of scientific evidence of EVT into real-world benefits. For instance, healthcare policies that influence critical time-matrices, endovascular thrombectomy techniques that may enhance success rate or prevent complications, or advanced imaging techniques that allow precise prognosis or expansion of treatment populations, should be evaluated. On the other hand, capturing LVO patients who were not able to undergo EVT may reveal the gap between clinical trials and real-world practice in the Asia-Pacific.\n\nIn this multicenter prospective collaboration across the Asian-Pacific, the investigators aim to evaluate the determinants of effective EVT in the real-world setting.",[196,188,65,29,525,526],"Brain Diseases","Major Adverse Cardiovascular Event","2026-03-16",{"date":505,"type":43},{"date":530,"type":43},"2022-10-21",{"date":532,"type":22},"2032-12-31",{"name":534,"class":50},"Chinese University of Hong Kong",3,{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":542,"eligibilityCriteria":543,"healthyVolunteers":12,"sex":18,"minAge":343,"maxAge":4,"enrollmentInfo":544,"targetDuration":4,"studyType":23,"phases":546,"briefSummary":547,"conditions":548,"keywords":549,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":4},"100627905","phase-3-testing-a-new-treatment-strategy-to-improve-secondary-stroke-prevention-for-older-adults-the-stroke75-trial-100627905","NCT07454707","Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial","Randomized Trial to Evaluate the Efficacy and Safety of Very Low Dose Anticoagulant Therapy Added to Standard-Care Single Antiplatelet Therapy for Prevention of Recurrent Strokes in Patients With Ischemic Stroke Aged 75+ Years","STROKE75+","Inclusion Criteria:\n\nParticipants must meet all of the following inclusion criteria to participate in the study:\n\n1. Age ≥75 years on the day of informed consent.\n2. Diagnosis of an acute ischemic stroke within the preceding 12 months, which was clinically symptomatic and confirmed by neuroimaging (CT or MRI), and for which the treatment plan is single antiplatelet therapy with either aspirin 81 mg daily (80 mg daily is permitted) or clopidogrel (75 mg daily) for long-term secondary stroke prevention.\n\n   \\[Note: The qualifying stroke event can be a clinical transient ischemic attack if there was neuroimaging evidence of acute ischemia\u002Finfarction on brain imaging. A clinically symptomatic acute intracranial vessel occlusion on angiography that recanalized without infarction is eligible for enrolment.\\]\n3. The patient has had ECG monitoring after the qualifying stroke event (Holter, telemetry, or other continuous ECG monitoring device) totalling at least 24 hours and with no episodes of atrial fibrillation (or atrial flutter) ≥6 minutes AND a routine 12-lead ECG within 90 days before randomization shows sinus rhythm (no atrial fibrillation or atrial flutter).\n4. Written informed consent from participant or legally authorized representative.\n\nExclusion Criteria:\n\nPatients meeting any of the following exclusion criteria at baseline are excluded from enrolment in the study:\n\n1. Diagnosis of atrial fibrillation or atrial flutter (AF) documented in the patient's medical history or examination; any AF on a 12-lead ECG; or any episode of AF ≥6 minutes on a Holter or other continuous ECG monitor.\n\n   \\[Note: The following are not exclusions and are acceptable for enrolment: brief subclinical device-detected AF with a maximum episode duration \\\u003C6 minutes on a continuous ECG recording; a remote history (\\>2 years ago) of transient AF that was only ever detected in the context of surgery or acute medical illness.\\]\n2. Any of the following 'major-risk' cardiac sources of embolism based on the patient's medical history and post-stroke echocardiography (transthoracic or transesophageal) or other cardiac imaging within the past 12 months: mechanical heart valve; intracardiac thrombus; atrial myxoma or other cardiac tumor; recent (\\\u003C4 weeks) myocardial infarction; or valvular vegetations or diagnosed\u002Fsuspected infective endocarditis.\n\n   \\[Note: The following are not exclusions and are acceptable for enrolment: bioprosthetic heart valve; TAVI; patent foramen ovale (PFO) with no plans for closure.\\]\n3. The patient has a medical requirement for chronic anticoagulant therapy or dual antiplatelet therapy, or dual or triple antithrombotic therapy (e.g. recent acute coronary syndrome or vascular stenting procedure, venous thromboembolism (DVT\u002FPE), hypercoagulable state) or chronic nonsteroidal anti-inflammatory drug (NSAID) therapy.\n4. The qualifying stroke etiology is attributed to vasculitis, arterial dissection, migraine, vasospasm, drug abuse, infective endocarditis, antiphospholipid antibody syndrome or other high-risk thrombophilia; Moya Moya; CADASIL or other genetic cause; other infectious or inflammatory cause; or an iatrogenic\u002Fprocedure-related cause (e.g. post-operative stroke).\n5. History of gastrointestinal bleeding or another major bleeding event within the past 12 months; active or recent spontaneous non-trivial bleeding (within the past 30 days); unresolved peptic ulcer; or considered by the enrolling investigator to be at high risk for serious bleeding for any reason.\n6. Hepatic disease associated with coagulopathy; acute hepatitis; chronic active hepatitis; severe hepatic disease (Child-Pugh class C); or cirrhosis.\n7. Receiving hemodialysis or peritoneal dialysis, or dialysis is planned within the next 12 months.\n8. History of CT-detected intracranial hemorrhage (intracerebral hemorrhage, subarachnoid hemorrhage, subdural hematoma, or epidural hematoma).\n\n   \\[Note: If there was head CT evidence of hemorrhagic transformation of the qualifying ischemic stroke, or other intracranial blood on head CT following the qualifying stroke event, then a head CT documenting resolution of hemorrhage must be obtained before randomization. Presence of asymptomatic incidental MRI-detected parenchymal brain microbleeds are not an exclusion, but cortical superficial siderosis or convexity subarachnoid hemorrhage are exclusions.\\]\n9. Uncontrolled hypertension (BP persistently \\>160 mmHg systolic or \\>100 mmHg diastolic) within the past 7 days before informed consent.\n10. Any of the following laboratory exclusions (must be based on the most recent available clinically acquired routine bloodwork within 90 days before randomization):\n\n    * calculated creatinine clearance \\\u003C30 mL\u002Fmin (Cockroft Gault);\n    * platelet count \\\u003C100 x 109\u002FL;\n    * hemoglobin \\\u003C100 g\u002FL;\n    * INR \\>1.3\n11. Body weight \\\u003C45 kg.\n12. The patient is receiving any of the following medications and is unable to stop or switch before randomization:\n\n    * Any anticoagulant drug. This includes unfractionated heparin (UFH); any low molecular weight heparin (LMWH) (e.g. enoxaparin, dalteparin, nadroparin, tinzaparin), fondaparinux, argatroban, or other injectable anticoagulant; warfarin (Coumadin), acenocoumarol, DOACs e.g. apixaban (Eliquis), dabigatran (Pradaxa), non-study edoxaban (Lixiana), rivaroxaban (Xarelto), or other oral anticoagulant; or\n    * Any antiplatelet medication other than aspirin 80 or 81 mg daily or clopidogrel 75 mg daily. This includes ticagrelor (Brillinta), prasugrel (Effient), dipyridamole, aspirin\u002Fextended-release dipyridamole (Aggrenox), cilostazol, Gp11b\u002FIIIa inhibitors e.g. abciximab (ReoPro), eptifibatide (Integrilin), tirofiban (Aggrastat), and others; or\n    * Dual antiplatelet therapy; or\n    * Daily nonsteroidal anti-inflammatory drug (NSAID) use; or\n    * Drugs expected to increase edoxaban concentration: cyclosporine, tacrolimus, quinidine, dronedarone, erythromycin, ketoconazole, itraconazole, HIV protease inhibitors (ritonavir, darunavir, atazanivir, and others), including nirmatrelvir\u002Fritonavir (Paxlovid) which may be prescribed for COVID-19 infection; or\n    * Drugs expected to decrease edoxaban concentration: carbamazepine, phenytoin, phenobarbital, primidone, valproic acid, rifampin\u002Frifampicin, St. John's wort.\n13. Total disability and dependence (modified Rankin scale score=5 at time of informed consent).\n14. The patient is likely to be poorly compliant or unreliable with medication intake or study follow-up appointments, or estimated life expectancy is \\\u003C1 year due to severe stroke, concomitant disease, or terminal illness.\n15. Known allergy\u002Fhypersensitivity to edoxaban or other contraindication to edoxaban.\n16. Any other condition that in the opinion of the enrolling physician would not permit the addition of edoxaban 15 mg once-daily to single antiplatelet therapy.\n17. Enrolment in another clinical trial involving a drug intervention, or enrolment in another clinical trial involving a non-drug intervention for stroke prevention or cardiovascular prevention.",{"count":545,"type":22},1204,[62],"The overall aim of this research is to improve secondary stroke prevention for older patients with stroke.\n\nIn current practice, patients with stroke are often prescribed antiplatelet therapy with either aspirin or clopidogrel to help prevent recurrent strokes. However, an antiplatelet medication may not be effective enough for some patients.\n\nA promising new treatment strategy to enhance stroke prevention involves a very low dose of an anticoagulant (anti-clotting medication) added to the standard antiplatelet therapy. In a previous study, this approach cut stroke risk in half among patients with heart\u002Fvascular disease, but it has not yet been formally tested in an older stroke population. The STROKE75+ trial is now being conducted to carefully evaluate the potential benefits and potential risks of this type of treatment strategy for secondary stroke prevention.\n\nThe medication being tested in the STROKE75+ trial is a commonly used anticoagulant called edoxaban -- at a reduced dose of 15mg once daily (one-quarter of its full dose) to minimize the chance of bleeding. In previous research, edoxaban 15mg daily has been shown to be safe and effective for preventing strokes in patients with atrial fibrillation, but it has not been studied in stroke patients without atrial fibrillation.\n\nThis trial aims to answer the following questions:\n\n1. Does the addition of edoxaban 15mg once a day to standard antiplatelet therapy reduce the risk of recurrent strokes more than standard antiplatelet therapy alone?\n2. Does the addition of edoxaban 15mg daily reduce the risk of severe (disabling) strokes, dementia, or heart attacks?\n3. What is the incidence of bleeding with\u002Fwithout edoxaban 15mg daily?\n\nThese questions will be addressed using a Randomized Clinical Trial design. Eligible participants are randomly assigned (50\u002F50 chance) to one of two study groups. Participants in Group 1 are treated with edoxaban 15 mg once a day by mouth (tablet) in addition to their usual standard antiplatelet medication. Participants in Group 2 will continue to take their standard antiplatelet medication (aspirin or clopidogrel) without edoxaban.\n\nParticipants are monitored closely for the duration of the study (approx.. 2-4 years). Every 3 months, participants will receive a phone call to check on their health status and assess if they have experienced any new strokes, bleeding, or other medical problems. Once a year, and at the start and end of the study, participants will also be asked questions about their symptoms, functioning, memory, and quality of life. At the end of the study, patient outcomes between the two groups will be compared and the results will be published.\n\nThe information gained from this study will increase knowledge and help inform future stroke care for the aging population. The ultimate goal of this research is to prevent more strokes, save lives, and reduce the growing public health burden of stroke.",[29],[188,550,551,552],"Secondary Stroke Prevention","Anticoagulation","Randomized Controlled Trial","2026-03-03",{"date":555,"type":43},"2026-03-06",{"date":557,"type":22},"2026-04",{"date":559,"type":22},"2031-12",{"name":561,"class":50},"Sunnybrook Health Sciences Centre",{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":568,"eligibilityCriteria":569,"healthyVolunteers":12,"sex":18,"minAge":570,"maxAge":366,"enrollmentInfo":571,"targetDuration":4,"studyType":23,"phases":573,"briefSummary":574,"conditions":575,"keywords":579,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":583,"startDateStruct":585,"completionDateStruct":587,"leadSponsor":589,"locationsCount":513},"100575082","urgent-carotid-endarterectomy-cea-versus-delayed-cea-in-symptomatic-carotid-stenosis-spread-staci-ii-100575082","NCT06767657","Urgent Carotid Endarterectomy (CEA) Versus Delayed CEA in Symptomatic Carotid Stenosis (SPREAD-STACI II)","Multicenter, Open-label Randomized Study Comparing Urgent Carotid Endarterectomy (CEA) (Within 72 Hours) Versus Delayed CEA (After 72 Hours) in Patients With Symptomatic Carotid Stenosis (SPREAD-STACI II)","Time_to_sCEA","Eligibility Criteria\n\nInclusion Criteria:\n\nPatients presenting with the following characteristics:\n\nDe novo stenosis of the carotid bifurcation and\u002For internal carotid artery origin, equal to or greater than 50% (NASCET method), diagnosed by color Doppler ultrasound, MR angiography (MRA), CT angiography (CTA), or catheter angiography.\n\nTIA or minor ischemic stroke (NIHSS ≤ 5) ipsilateral to the carotid stenosis, occurring within the previous 24 hours.\n\nPreserved consciousness and neurologically stable symptoms. No evidence of ongoing cerebral ischemia, or evidence of cerebral ischemia with a diameter \\\u003C25 mm.\n\nAge between 45 and 90 years. ASA score \\\u003C 4. Ability to comply with follow-up requirements as specified. Willingness to provide informed consent for participation in the study.\n\nA patient with an NIHSS ≤ 5 who is aphasic may be unable to provide consent. In these cases:\n\nThe attending physician assesses the feasibility of including the patient. Family members are informed but, under Italian law, cannot provide consent. A third-party physician certifies that the patient meets the inclusion criteria.\n\nThe attending physician signs the appropriate form, and randomization proceeds. If and when the patient regains the ability to provide or refuse consent, the informed consent form will be presented to them. Should they decline, their data will be removed from the study database.\n\nAdditionally, the study includes patients who underwent thrombolysis and\u002For mechanical thrombectomy after the onset of the index symptom, followed by a brain CT\u002FMRI without secondary cerebral hemorrhage (PH1, PH2, or PHr).\n\nExclusion Criteria:\n\nStenosis \\\u003C 50% (NASCET method) at the bifurcation and\u002For internal carotid artery origin, diagnosed by ECD, CTA, or MRA.\n\nCarotid thrombosis or dissection. NIHSS \\> 5. Cerebral hemorrhage. Impaired consciousness or neurologically unstable condition. Cancer, any condition with a poor prognosis, major cardiopathy, or any severe neurological disorder.\n\nCT or MRI evidence of cerebral ischemia \\> 25 mm in diameter. CT or MRI evidence of cerebral lesions of uncertain origin. Recurrent TIA or stroke-in-evolution. Age \\\u003C 45 years or \\> 90 years. ASA risk score = 4. Lack of informed consent. Inability to undergo CEA within 72 hours of the initial ischemic symptom. Inability to participate in a 90-day follow-up after the initial ischemic symptom.\n\nPrevious CEA or stenting of the examined carotid artery.","45 Years",{"count":572,"type":22},456,[115],"In patients with internal carotid artery (ICA) stenosis of 50% or greater (measured according to the criteria of the North American Symptomatic Carotid Endarterectomy Trial (NASCET)) who have experienced a transient ischemic attack (TIA) or minor ipsilateral stroke, carotid endarterectomy (CEA) offers maximum benefit if performed within 15 days of the initial ischemic symptom. National and international guidelines recommend surgical treatment (CEA) within this timeframe; however, no studies have specifically evaluated the optimal timing for CEA after a TIA or minor stroke.\n\nIt is well established that the risk of a major stroke is highest in the first few days following a transient ischemic attack or minor stroke and then decreases over the subsequent days and weeks.\n\nThis raises the hypothesis that performing an urgent carotid endarterectomy (within 3 days) may provide greater benefit compared to a delayed procedure (between 4 and 15 days).",[29,576,577,578],"Transient Ischemic Accident","Endarterectomy, Carotid","Stroke Prevention",[91,580,581,582],"endarterectomy","transient ischemic accident","stroke prevention",{"date":584,"type":43},"2026-03-04",{"date":586,"type":43},"2025-07-03",{"date":588,"type":22},"2028-01-01",{"name":590,"class":50},"Italian Society of Vascular and Endovascular Surgery",{"id":592,"slug":593,"hasResults":12,"nctId":594,"briefTitle":595,"officialTitle":595,"acronym":596,"eligibilityCriteria":597,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":276,"enrollmentInfo":598,"targetDuration":4,"studyType":23,"phases":600,"briefSummary":601,"conditions":602,"keywords":605,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":608,"lastUpdatePostDateStruct":609,"startDateStruct":610,"completionDateStruct":612,"leadSponsor":614,"locationsCount":51},"100507236","early-upper-limb-rehabilitation-with-eeg-neurofeedback-after-stroke-100507236","NCT05884762","earlY Upper Limb Rehabilitation WIth EEG-Neurofeedback After Stroke","YUWIN-Stroke","Inclusion Criteria:\n\n* Unilateral ischaemic or haemorrhagic stroke\n* Adult (18-80 years), both sexes\n* Stroke \\\u003C 3 weeks\n* Upper limb deficit defined by Shoulder Abduction Finger Extension score \\\u003C5 measured during the 7 days following stroke; i.e., patients predicted to have incomplete recovery\n* No participation-limiting comprehension problems\n* With or without homonymous lateral hemianopia; with or without visuospatial hemineglect\n* Free, informed and written consent signed by the patient or a member of the patient's family (in the case of a patient who is able to understand the information and give consent but has motor difficulties resulting in an invalid signature).\n* Affiliated to french social security\n\nExclusion Criteria:\n\n* Ischemic or hemorrhagic brain stem and\u002For cerebellum involvement\n* Multiple strokes\n* Stroke \\\u003C 1 week; in order not to be deleterious by starting active rehabilitation too early after immediate stroke\n* Aphasia with major comprehension impairment\n* Contraindication to MRI\n\n  * pacemaker or implantable defibrillator,\n  * neurosurgical clips,\n  * cochlear implants,\n  * intra-orbital or encephalic metallic foreign bodies,\n  * stents placed less than 4 weeks ago and osteosynthesis devices placed less than 6 weeks ago,\n  * claustrophobia. (Patients who have undergone thrombolysis or thrombectomy may be included in the study.)",{"count":599,"type":22},40,[115],"The aim of this study is to evaluate the effect of early rehabilitation treatment by electroencephalographic neurofeedback on upper limb motor function after stroke.\n\nResearchers will compare :\n\nInterventional group: electroencephalographic neurofeedback + traditional reference rehabilitation programme Control group: SHAM electroencephalographic neurofeedback + traditional reference rehabilitation programme",[188,30,29,603,604],"Stroke Rehabilitation","Brain Infarction",[188,429,606,607],"neurofeedback","Upper Limb","2026-02-26",{"date":553,"type":43},{"date":611,"type":43},"2024-02-20",{"date":613,"type":22},"2027-11",{"name":615,"class":50},"Rennes University Hospital",{"id":617,"slug":618,"hasResults":12,"nctId":619,"briefTitle":620,"officialTitle":621,"acronym":4,"eligibilityCriteria":622,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":623,"enrollmentInfo":624,"targetDuration":4,"studyType":23,"phases":626,"briefSummary":627,"conditions":628,"keywords":630,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":633,"lastUpdatePostDateStruct":634,"startDateStruct":636,"completionDateStruct":638,"leadSponsor":640,"locationsCount":51},"100516224","utility-of-cc7-transfer-in-stroke-subtypes-100516224","NCT06001736","Utility of CC7 Transfer in Stroke Subtypes","Seventh Cervical Nerve Transfer for Spastic Arm Paresis: A Prospective Analysis of Efficacy in Ischemic vs. Hemorrhagic Stroke","Inclusion Criteria:\n\n* History of ischemic or hemorrhagic stroke with resultant arm paresis that has ceased to improve within 1-5 years of rehabilitation.\n* baseline Fugl-Meyer score below 33\n\nExclusion Criteria:\n\n* pregnancy","65 Years",{"count":625,"type":22},95,[115],"The purpose of this study is to evaluate the limb functional improvement after contralateral C7 root transfer in stroke patients.",[29,30,629],"Spastic Hemiparesis",[324,631,632],"Hemorrhagic stroke","Spastic hemiparesis","2026-02-25",{"date":635,"type":43},"2026-02-27",{"date":637,"type":43},"2022-03-13",{"date":639,"type":22},"2027-03-01",{"name":641,"class":50},"Dartmouth-Hitchcock Medical Center",{"id":643,"slug":644,"hasResults":12,"nctId":645,"briefTitle":646,"officialTitle":647,"acronym":4,"eligibilityCriteria":648,"healthyVolunteers":649,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":650,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":652,"conditions":653,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":659,"lastUpdatePostDateStruct":660,"startDateStruct":662,"completionDateStruct":664,"leadSponsor":666,"locationsCount":51},"100438662","impact-of-covid-19-vaccines-on-cerebrovascular-health-100438662","NCT04992195","Impact of COVID-19 Vaccines on Cerebrovascular Health","Impact of COVID-19 Vaccines on Cerebrovascular Health - a Population-based Study","Inclusion Criteria:\n\nAll consecutive citizens in the CUHK Brain Health Longitudinal Study cohort who received baseline MRI brain.\n\nExclusion Criteria:\n\n1. Citizens with clinically evident stroke or dementia prior to recruitment; or\n2. Citizens who are unable to provide an informed consent; or\n3. Citizen with contraindications to MRI brain, e.g., non-MRI compatible implants, claustrophobia, etc; or\n4. Citizens who had no baseline MRI brain assessment.",true,{"count":651,"type":22},500,"Safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines may reduce the transmission of and achieve population immunity against the COVID-19 pandemic, which accounted for more than 3.75million deaths worldwide. With World Health Organization's (WHO) effort on ensuring equitable access to COVID-19 vaccines, vaccination rate may increase in the near future.\n\nOn the other hand, vaccination hesitancy has emerged as a major hindrance on the global vaccination campaigns in certain areas due to safety concerns, social factors, and public health policies. For instance, a recent survey conducted in Hong Kong showed a low vaccine acceptance rate of 37%. Long-term safety concerns and post-vaccination events relayed by the social media maybe reasons for vaccination hesitancy. Among which, cerebrovascular accidents (CVA) after vaccination were one of the most frequently reported post-vaccination events. These reports ranged from ischemic strokes in elderly patients with multiple cardiovascular co-morbidities, to hemorrhage strokes in otherwise \"young-and-fit\" adults. While many of these events were investigated by the COVID-19 immunization expert committee, an important premise to address the apprehension of CVA after vaccination is the provision of evidence-based information of the impact of COVID-19 vaccines on brain health.\n\nIn this prospective, longitudinal, observational study, we aim to elucidate the relationship between COVID-19 vaccines and cerebrovascular health in healthy citizens in a population-based cohort.",[188,65,29,654,655,656,525,526,657,658],"Dementia","Brain Ischemia","Alzheimer Disease","Arterial Thromboembolism","Venous Thromboembolism","2026-02-21",{"date":661,"type":43},"2026-02-24",{"date":663,"type":43},"2021-07-05",{"date":665,"type":22},"2026-12-31",{"name":534,"class":50},{"id":668,"slug":669,"hasResults":12,"nctId":670,"briefTitle":671,"officialTitle":671,"acronym":672,"eligibilityCriteria":673,"healthyVolunteers":649,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":674,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":676,"conditions":677,"keywords":683,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":659,"lastUpdatePostDateStruct":688,"startDateStruct":689,"completionDateStruct":691,"leadSponsor":693,"locationsCount":513},"100331231","cuhk-brain-health-longitudinal-study-100331231","NCT03592563","CUHK Brain Health Longitudinal Study","BHS","Inclusion Criteria:\n\n1. Adult ≥ 18 years of age\n2. Fulfilling criteria for membership in one of these three groups:\n\n   * Red group: established diagnosis of one or more neurological and\u002For psychiatric conditions\n   * Yellow group: high-risk to develop one or more neurological and\u002For psychiatric conditions\n\n     1. family history (first degree relative) one or more neurological and\u002For psychiatric conditions\n     2. examination, imaging or laboratory findings consistent with pre-symptomatic stages of one or more neurological and\u002For psychiatric disorders\n   * Green group: not meeting criteria for Red or Yellow groups, but interested in longitudinal research on maintenance and\u002For improvement of brain health\n3. Subject provides informed consent by signing and dating the written informed consent form\n4. Subject is willing to answer health questionnaires and be followed longitudinally\n\nExclusion Criteria:\n\n* None",{"count":675,"type":22},5000,"The goal of this study is to develop a large longitudinal cohort of individuals diagnosed with or at high risk for brain diseases (both neurological and psychiatric in nature), in order to identify risk factors that contribute to neurological and psychiatric diseases over time. The investigators seek to capture relevant information from medical records, electronically administered questionnaires and follow up phone-based interviews. The investigators expect to eventually have sufficient power from our dataset to examine risk factors for a variety of brain disorders, both individually and in aggregate. Our ultimate goal is to offer scientifically validated ways to preserve and promote brain health by working with our patients' needs and tracking their progress over time.",[29,678,188,65,654,655,525,656,679,680,681,682],"Stroke Syndrome","Health Attitude","Health Knowledge, Attitudes, Practice","Health Personnel Attitude","Healthy Aging",[91,684,685,686,687],"dementia","Alzheimer disease","Health Brain","Health knowledge",{"date":661,"type":43},{"date":690,"type":43},"2019-07-01",{"date":692,"type":22},"2048-12-31",{"name":534,"class":50}]